Cavanal Hill Funds has disclosed its financial details in a recent filing, providing insights into its asset management strategies and overall financial health. The filing, submitted on October 29, 2026, outlines the company’s total assets, liabilities, and net assets, which are crucial for understanding its performance in the investment sector.
As of August 31, 2026, Cavanal Hill Funds reported total assets amounting to approximately $22.13 million, with total liabilities of around $119,828. This results in net assets of approximately $22.01 million. Such figures are indicative of the company’s ability to manage its investments effectively and maintain a stable financial footing.
Background
Cavanal Hill Funds is an investment entity incorporated in Ohio. The company is known for managing various investment funds, including its Limited Duration Fund. The recent filing is part of a series of submissions, including several NPORT-P forms filed on the same day, which typically detail the portfolio holdings and financial metrics of the funds managed by the company.
What the Filing Says
The NPORT-P filing reveals key financial metrics for Cavanal Hill Funds, stating, "Total assets: $22,131,992.54; Total liabilities: $119,827.75; Net assets: $22,012,164.79." These figures provide a snapshot of the company's financial health and its capacity to manage investments.
Impact
The information disclosed in this filing may affect investors and stakeholders within the investment management industry. With competitors closely monitoring Cavanal Hill Funds' performance, this update could influence market strategies and investor decisions. The filing may also impact how potential investors view the company's stability and growth prospects.
What's Next
The filing does not specify what happens next for Cavanal Hill Funds. However, continued monitoring of its financial performance and potential future filings will be essential for stakeholders and investors interested in the company's trajectory.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






